The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is
localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm …

The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen
Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy …

Chimeric antigen receptor (CAR) T cells represent a revolutionary immunotherapy that
allows specific tumor recognition by a unique single-chain fragment variable (scFv) derived …

T-cell redirecting therapies (TCRTs), such as CAR-or TCR T-cells and T-cell engagers, have
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment
outcome, especially in patients that are ineligible for intensive chemotherapy …

Recent times have witnessed remarkable progress in cancer immunotherapy, drastically
changing the cancer treatment landscape. Among the various immunotherapeutic …

The nucleophosmin (NPM1) gene encodes for the most abundant nucleolar protein. Thanks
to its property to act as histone chaperone and to shuttle between the nucleus and …

Although adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells has
achieved unprecedented response rates in patients with certain hematological …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …